New Inverted Light-Sheet Microscopy Platform for Research and Clinical Applications
"Partnering with ZEISS represents a significant step forward in our mission to revolutionize pathology by extracting and analysing the wealth of information contained in every single cell of a biopsy, rather than relying on just a small fraction of the tissue," said Dr. Nicholas Reder, CEO of Alpenglow Biosciences. "ZEISS's long-standing history of innovation in light-sheet microscopy is the perfect complement to our cutting-edge software and AI capabilities. Together, we will innovate and expand our existing 3D pathology platform that not only advances the needs of biopharma but also transforms clinical practice."
By combining the industry-leading technologies of Alpenglow and ZEISS, the collaboration will enable the broader adoption of 3D pathology across research, translational and clinical applications. As part of the multi-phased collaboration, the companies will develop key applications in: Enhanced 3D pathology workflows (enabling microtome-free, direct digitization of entire tissue samples for improved 3D diagnostics and workflow efficiency), translational research (studying disease biology across 3D volumes enabling detection of immune cell infiltration patterns and characterization of novel biomarkers), drug development (understanding mechanisms of action and optimizing patient selection for clinical trial samples), AI-enabled clinical decision support (predicting treatment response and patient prognosis using AI-driven analysis of rich 3D imaging datasets).
JENA, Germany & SEATTLE, May 06, 2025 --( BUSINESS WIRE )--ZEISS and Alpenglow Biosciences today announced a new partnership to jointly develop an inverted light-sheet microscope and bioinformatics pipeline tailored specifically for clinical applications. Alpenglow, a pioneering 3D spatial biology company specializing in open-top light-sheet microscopy, data processing, and AI-driven analysis for biopharma and clinical applications, has partnered with ZEISS, a global leader in light-sheet imaging technologies and visualization software – including ZEISS Lattice Lightsheet 7 and arivis software.
Story Continues
Dr. Albiez further emphasized, "At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Alpenglow marks a significant milestone in advancing workflows for clinical pathology. Together, we are introducing an integrated solution for analysing entire tissue samples and improving reproducibility to meet the evolving needs of both translational research and clinical settings. This collaboration will enable researchers and clinicians to gain deeper insights into tissue and cellular structures with greater efficiency and precision, ultimately facilitating more personalized and effective treatments."
The partnership will create the fastest whole tissue imaging solution by combining exacting engineering and arivis visualization platform from ZEISS with Alpenglow's innovative data processing and AI capabilities. Once imaged, a GPU-accelerated imaging analytics pipeline could allow users to go from tissue to clinically impactful insights at the same time or faster than traditional pathology workflows. The generation of 3D images from entire tissues provides the perfect substrate for AI to make individualized treatment predictions for patients. Ultimately, these innovative technologies will deliver tools that streamline pathology workflows and enable earlier, more accurate clinical decision-making.
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue around 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research, and medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world's leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
With a portfolio aligned with future growth areas like digitalization, healthcare and Smart Production and a strong brand, ZEISS is shaping the future of technology and constantly advancing the world of optics and related fields with its solutions. The company's significant, sustainable investments in research and development lay the foundation for the success and continued expansion of ZEISS' technology and market leadership. ZEISS invests 15 percent of its revenue in research and development – this high level of expenditure has a long tradition at ZEISS and is also an investment in the future.
With over 46,000 employees, ZEISS is active globally in around 50 countries with more than 60 sales and service locations, around 40 research and development facilities, and 35 production facilities worldwide (30 September 2024). Founded in 1846 in Jena, the company is headquartered in Oberkochen, Germany. The Carl Zeiss Foundation, one of the largest foundations in Germany committed to the promotion of science, is the sole owner of the holding company, Carl Zeiss AG.
Further information at www.zeiss.com
ZEISS Research Microscopy Solutions
ZEISS Research Microscopy Solutions is the leading provider of light, electron, X-ray microscope systems, correlative microscopy and software solutions leveraging AI technologies. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical routine applications. The unit is headquartered in Jena. Additional production and development sites are located in Germany, UK, USA and China. ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.
Further information at www.zeiss.com/microscopy
About Alpenglow Biosciences
Alpenglow Biosciences is a 3D spatial biology company focused on accelerating drug development and improving clinical diagnostics with AI-enabled 3D imaging technology. Their platform solution provides new spatial biology insights with greater accuracy by non-destructively digitizing entire tissues. Alpenglow partners with pharmaceutical companies to bring better therapeutics to market faster through greater understanding of mechanism of action, efficacy & toxicology, and clinical trial enrollment using their patented platform. See what you've been missing at alpenglowbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506763819/en/
Contacts
Press contact
ZEISS Research Microscopy Solutions
Vybhav Sinha
Phone: +49 3641 64 3949
Email: press.microscopy@zeiss.com
www.zeiss.com/newsroom
Alpenglow Biosciences
Sarah Malik
Phone: (206) 455-3170
Email: media@alpenglowbiosciences.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Trump Floats Deal to Let Nvidia's Blackwell Chips Into China -- With a 50% Power Cut
President Donald Trump has signaled he may be open to letting Nvidia (NASDAQ:NVDA) ship a toned-down version of its most advanced Blackwell AI chip to China if the company trims its capabilities by 30% to 50%. The comment comes shortly after Trump confirmed an unusual arrangement already in place for Nvidia's less-powerful H20 chip, which allows exports to China in exchange for a 15% revenue share paid directly to the US government. Advanced Micro Devices will follow the same formula for its MI308 chip, according to a person familiar with the matter. Nvidia has not commented on the president's remarks. Warning! GuruFocus has detected 5 Warning Signs with NVDA. The potential deal for Blackwell would mirror Trump's broader push to secure financial returns for the US in exchange for loosening certain export restrictions a strategy that could influence how American companies negotiate market access in China. While Trump didn't outline a specific timeline, he suggested Nvidia CEO Jensen Huang could soon meet with him to discuss a negatively enhanced Blackwell variant. If approved, the move could mark a shift in how high-end US chip technology is selectively offered abroad. Nvidia's Blackwell chips are the backbone of today's most powerful AI systems but remain off-limits to China under current US rules. Both Nvidia and AMD (NASDAQ:AMD) have taken revenue hits as tighter controls limited exports to older models on par with domestic Chinese alternatives products that have struggled to gain traction. Nvidia has already said it is developing another China-specific chip and will seek approval to sell it. The company noted that further cutting back its Hopper-based H20 chip is no longer viable, suggesting a modified Blackwell could be the clearest path to regaining momentum in one of the world's largest AI markets. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
ProSieben investor General Atlantic opts for Czech PPF offer, shuns MFE, sources say
MUNICH (Reuters) -Financial investor General Atlantic has tendered its 2.4% stake in German media group ProSiebenSat.1 to Czech investment company PPF, two people familiar with the matter told Reuters on Tuesday. By taking PPF's cash offer of 7 euros ($8.17) per share for ProSieben, General Atlantic is going against the endorsement of ProSieben's management for a higher rival offer by MFE-MediaForEurope, which is partly paid in MFE shares, indicating that MFE faces some difficulties in its bid for control over ProSieben. General Atlantic, PPF and ProSieben declined to comment. MFE did not immediately respond to a request for comment. ($1 = 0.8567 euros)
Yahoo
27 minutes ago
- Yahoo
BBC Radio Scotland's Bryan Burnett to return to airwaves after cancer treatment
BBC Radio Scotland presenter Bryan Burnett will return to the airwaves on Thursday after undergoing cancer treatment. The broadcaster announced in June he would step back from his programme Get It On to receive care for appendix cancer. Fellow presenter Grant Stott, who stepped in during his absence, announced his return to listeners on Tuesday night. He said: 'In what must have been a terrible time for Bryan and his family and close friends, I'm just delighted I was able to help by looking after something that is very precious to Bryan; Get It On and his listeners. 'Getting to do the show over this time has shown me just how close the audience is to Bryan and vice versa. 'I know they will be delighted to get their radio teatime pal back.' Burnett said his treatment had been successful and thanked those who had wished him well throughout his recovery. Commenting on his return, he said: 'I am delighted to be returning to work following successful treatment for appendix cancer. 'Over the past few months I have been focused on my recovery and have been supported by an incredible medical team, my family and friends, and the overwhelming kindness of so many BBC Radio Scotland listeners who have reached out with encouragement and well-wishes. 'Their messages, cards and kindness have meant so much. 'My team at the BBC have also been a huge support and I want to thank Grant Stott, who has been sitting in for me and done such a great job looking after the show. 'My return to work will be gradual to ensure I maintain my health and energy. Cancer has given me a renewed perspective on what matters most and I am excited about the road ahead and grateful for the opportunity to return to doing what I'm passionate about.' Hayley Valentine, director BBC Scotland, said: 'Like the Get it On listeners, everyone at BBC Scotland is delighted to be welcoming Bryan back to the studio following what has been a tough couple of months for him. We look forward to seeing and hearing him back where he belongs.' Stott will share Get it On presenting duties with Bryan during his phased return. Burnett's first Get it On show will be Thursday 14 August 14 6pm to 8pm.
